Sun Pharma launches Cequa, maiden dry eye treatment with nanomicellar technology in Canada

Sun Pharma Canada Inc today launched Cequa, a new treatment for Canadians living with dry eye disease. Cequa (cyclosporine ophthalmic solution 0.09 per cent w/v), a calcineurin inhibitor immunomodulator, is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration, the company said in a statement.

The statement quoted Abhay Gandhi, CEO, North America, Sun Pharma, as saying that this launch is an important milestone for Sun Pharma as the company expands its ophthalmics portfolio into Canada.

A recent report from the Centre for Ocular Research and Education (CORE) has shown that rates of dry eye disease are on the rise due to an increase in mask wearing, which can lead to dry spots on the ocular surface, the statement added.

“Cequa, with its nanomicellar technology and increased strength of cyclosporine, can be an important addition to our treatment options as eye care professionals strive for more personalised treatment,” the statement quoted W Bruce Jackson, MD, former Professor and Chair, Department of Ophthalmology, McGill University and the University of Ottawa.